Protein Markers Predict Risk of Melanoma Recurrence

Dec 03, 2009

(PhysOrg.com) -- A new prognostic tool that can determine the risk of recurrence in melanoma patients has been developed by researchers at Yale Cancer Center. The technology, based on five proteins expressed in melanoma tissue, can classify patients into a low-risk group, with 10% chance of recurrence at eight years, or a high-risk group that has a 40% probability of recurrence within that time. The study appears in the December 1 issue of the Journal of Clinical Oncology.

Twenty to sixty percent of patients with stage II will later be diagnosed with metastatic melanoma due to a recurrence of their disease. This new tool will help to identify patients who are at increased risk for recurrence so that they can be more carefully monitored.

“This test has the potential to really help melanoma patients and their clinicians decide how to manage their disease,” said David L. Rimm, M.D., Ph.D., lead author and professor of pathology at Yale School of Medicine.

The Yale Cancer Center research team analyzed protein expression from a historic group of tumor samples from patients taken from 1959 to 1994 and then tested it on an independent group of patient samples from surgery performed by Dr. Stephan Ariyan, clinical professor of surgery and director of the Yale Cancer Center Melanoma Program.

The prognostic tool is based on the AQUA™ system, a technology developed at Yale School of Medicine by Rimm and Robert L. Camp, M.D. AQUA automatically measures and localizes specific variations in protein expression within tissue with a high level of precision. The multi-tissue proteomic analysis system combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies.

HistoRx, a biotechnology company based in New Haven, has an exclusive license for the AQUA™system.

More information: J Clin Oncol. 2009 Dec 1;27(34):5772-80.

Provided by Yale University (news : web)

Explore further: Scientists link gene to tamoxifen-resistant breast cancers

add to favorites email to friend print save as pdf

Related Stories

Protein may be linked to melanoma recurrence

Jun 02, 2007

Higher levels of a protein called S-100 in patients with melanoma may correlate with a higher risk of having the disease return, say researchers at the University of Pittsburgh Cancer Institute (UPCI), who presented their ...

Radiation after surgery reduces chance of melanoma returning

Nov 02, 2009

High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy ...

Biomarker predicts disease recurrence in colorectal cancer

Feb 17, 2009

Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurr ...

New combination therapy safe, promising for melanoma patients

Jun 01, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.